There appear to be no legitimate sources for 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT as marketed drugs and no accepted medical use in the United States, but DEA notes that these substances are available for purchase from legitimate suppliers for scientific research. There is no evidence of significant diversion of 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT from legitimate suppliers.

DEA has identified 31 domestic suppliers of one or more of the following substances: 4-hydroxy-*N,N*-diisopropyltryptamine (4-OH-DiPT), 5-methoxy-*alpha*-methyltryptamine (5-MeO-AMT), 5-methoxy-*N*-methyl-*N*-isopropyltryptamine (5-MeO-MiPT), 5-methoxy-*N,N*-diethyltryptamine (5-MeO-DET), and *N,N*-diisopropyltryptamine (DiPT). Thirty (30) of the 31 domestic suppliers are not registered with DEA to handle controlled substances. The one registered supplier is already registered with DEA and has all security and other handling processes in place, resulting in minimal impact to this supplier. Therefore, the remaining 30 non-registered domestic suppliers are affected. Since the vast majority of DEA registrants are small entities or are employed by small entities, all 30 affected suppliers are assumed to be small entities. It is impossible to know how much 4-hydroxy-*N,N*-diisopropyltryptamine (4-OH-DiPT), 5-methoxy-*alpha*-methyltryptamine (5-MeO-AMT), 5-methoxy-*N*-methyl-*N*-isopropyltryptamine (5-MeO-MiPT), 5-methoxy-*N,N*-diethyltryptamine (5-MeO-DET), and *N,N*-diisopropyltryptamine (DiPT) are distributed by these suppliers. It is common for suppliers to have items on their catalog while not actually having any material level of sales. Based on the discussion above, DEA believes any quantity of sales from these distributors for legitimate purposes is minimal. Therefore, these suppliers are expected to remove the product from their catalog rather than incur the cost of obtaining a DEA registration and physical security for products with minimal sales. Therefore, DEA estimates the cost of this rule, in form of lost sales, if any, on the affected small entities is minimal. DEA welcomes any public comment regarding this estimate.

Because of these facts, this proposed rule will not, if promulgated, result in a significant economic impact on a substantial number of small entities.

Unfunded Mandates Reform Act of 1995

On the basis of information contained in the ''Regulatory Flexibility Act'' section above, DEA has determined pursuant to the Unfunded Mandates Reform Act (UMRA) of 1995 (2 U.S.C. 1501 *et seq.*) that this proposed action would not result in any Federal mandate that may result ''in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of $100,000,000 or more (adjusted annually for inflation) in any 1 year . . . .'' Therefore, neither a Small Government Agency Plan nor any other action is required under UMRA of 1995.

List of Subjects in 21 CFR Part 1308

Administrative practice and procedure, Drug traffic control, Reporting and recordkeeping requirements.

For the reasons set out above, DEA proposes to amend 21 CFR part 1308 as follows:

PART 1308—SCHEDULES OF CONTROLLED SUBSTANCES

■ 1. The authority citation for 21 CFR part 1308 continues to read as follows:

Authority: 21 U.S.C. 811, 812, 871(b), 956(b), unless otherwise noted.

■ 2. In § 1308.11, as proposed to be amended at 86 FR 16553 (March 30, 2021), 86 FR 37719 (July 16, 2021), and 86 FR 69187 (December 7, 2021), add paragraphs (d)(101) through (105) to read as follows:

§ 1308.11 Schedule I.

* * * * *

(d) * * *

(101) 4-hydroxy-*N,N*-diisopropyltryptamine (other names: 4-OH-DiPT; 3-(2-(diisopropylamino)ethyl)-1*H*-indol-4-ol) 7516.

(102) 5-methoxy-*alpha*-methyltryptamine (Other names: 5-MeO-AMT; 1-(5-methoxy-1*H*-indol-3-yl)propan-2-amine) 7506.

(103) 5-methoxy-*N*-methyl-*N*-isopropyltryptamine (Other names: 5-MeO-MiPT; *N*-(2-(5-methoxy-1*H*-indol-3-yl)ethyl)-*N*-methylpropan-2-amine) 7512.

(104) 5-methoxy-*N,N*-diethyltryptamine (Other names: 5-MeO-DET; *N,N*-diethyl-2-(5-methoxy-1*H*-indol-3-yl)ethanamine) 7525.

(105) *N,N*-diisopropyltryptamine (Other names: DiPT; *N*-(2-(1*H*-indol-3-yl)ethyl)-*N*-isopropylpropan-2-amine) 7522.

* * * * *

Anne Milgram,

Administrator.

[FR Doc. 2022–00713 Filed 1–13–22; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF THE INTERIOR

National Indian Gaming Commission

25 CFR Part 537

RIN 3141–AA58

Background Investigations for Persons or Entities With a Financial Interest in or Having a Management Responsibility for a Management Contract; Correction

AGENCY: National Indian Gaming Commission, Department of the Interior.

ACTION: Proposed rule; correction.

SUMMARY: This document corrects the preamble to a proposed rule published in the **Federal Register** of December 2, 2021, regarding Background Investigations for Persons or Entities with a Financial Interest in or Having a Management Responsibility for a Management Contract. The document contained incorrect dates for submitting comments. This correction clarifies that comments are due January 31, 2022.

FOR FURTHER INFORMATION CONTACT: Michael Hoenig, 202–632–7003.

SUPPLEMENTARY INFORMATION:

Correction

In the **Federal Register** of December 2, 2021, in proposed rule FR Doc. 2021–25844, on page 68446, in the second column, change the **DATES** caption to read:

DATES: Written comments on this proposed rule must be received on or before January 31, 2022.

Dated: January 6, 2022.

Michael Hoenig,

General Counsel.

[FR Doc. 2022–00631 Filed 1–13–22; 8:45 am]

BILLING CODE 7565–01–P

DEPARTMENT OF THE INTERIOR

National Indian Gaming Commission

25 CFR Part 537

RIN 3141–AA77

Fees; Correction

AGENCY: National Indian Gaming Commission, Department of the Interior.

ACTION: Proposed rule; correction.

SUMMARY: This document corrects the preamble to a proposed rule published in the **Federal Register** of December 2, 2021, regarding Fees. The document contained incorrect dates for submitting comments. This correction clarifies that comments are due January 31, 2022.